Clinical Data

positive negative up down good bad mixed

Biotech

Tyra rolls toward pivotal cancer study even as stock deflates

Tyra reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year.

Nick Paul Taylor Sep 9, 2026 9:30am

COPD

AZ's 'science success story' with tozorakimab plays out in full

Sep 8, 2026 10:50am

BMS

BMS’ pivotal CAR-T multiple myeloma trial hits primary endpoint

Sep 8, 2026 9:11am

Wool heart

Don't count out Alnylam's next-gen silencer in ATTR-CM: analysts

Sep 1, 2026 1:55pm

ESMO AstraZeneca

AstraZeneca's heart failure drug shows promise in ph. 2 trial

Aug 31, 2026 11:13am

Close up shot of the target from a dart game

Taiho and Cullinan secure lung cancer victory to challenge J&J

Aug 13, 2026 6:00am